Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 19/20 | 0.47 |
| ▸ | AKT1 | P31749 | 19/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17023906 | 0.88 | RPS6KB1 (0.50) | RPS6KB1AKT1 | |
| SCHEMBL17023914 | 0.88 | RPS6KB1 (0.50) | RPS6KB1AKT1 | |
| SCHEMBL14782551 | 0.86 | RPS6KB1 (0.60) | RPS6KB1AKT1 | |
| SCHEMBL14783006 | 0.86 | RPS6KB1 (0.59) | RPS6KB1AKT1 | |
| SCHEMBL15720181 | 0.85 | RPS6KB1 (0.54) | RPS6KB1AKT1 | |
| SCHEMBL15719360 | 0.84 | MEN1 (0.46) | RPS6KB1AKT1MEN1KMT2A | |
| SCHEMBL14782369 | 0.83 | RPS6KB1 (0.64) | RPS6KB1AKT1 | |
| SCHEMBL14782595 | 0.82 | RPS6KB1 (0.63) | RPS6KB1AKT1 | |
| SCHEMBL14782570 | 0.82 | RPS6KB1 (0.63) | RPS6KB1AKT1 | |
| SCHEMBL14782657 | 0.82 | RPS6KB1 (0.64) | RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299362-B1 | IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3299362-A1 | IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9315517-B2 | Imidazol-piperidinyl derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| EP-2920154-A1 | NOVEL IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MAP4K2, MAP4K3, MAP3K4 | RPS6KB1 318/4885AKT1 197/4885MEN1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.